U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21N5O2
Molecular Weight 339.3916
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALOGLIPTIN

SMILES

CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O

InChI

InChIKey=ZSBOMTDTBDDKMP-OAHLLOKOSA-N
InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H21N5O2
Molecular Weight 339.3916
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
NESINA

Cmax

ValueDoseCo-administeredAnalytePopulation
165 ng/mL
25 mg 1 times / day steady-state, oral
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
154.83 ng/mL
25 mg 1 times / day multiple, oral
ALOGLIPTIN plasma
Homo sapiens
335.36 ng/mL
50 mg 1 times / day multiple, oral
ALOGLIPTIN plasma
Homo sapiens
75.38 ng/mL
12.5 mg 1 times / day multiple, oral
ALOGLIPTIN plasma
Homo sapiens
114.08 ng/mL
25 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
246 ng/mL
50 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
55.28 ng/mL
12.5 mg single, oral
ALOGLIPTIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1511 ng × h/mL
25 mg 1 times / day steady-state, oral
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
1174.76 ng*h/mL
25 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
1625.58 ng*h/mL
25 mg 1 times / day multiple, oral
ALOGLIPTIN plasma
Homo sapiens
2488.48 ng*h/mL
50 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
3389.21 ng*h/mL
50 mg 1 times / day multiple, oral
ALOGLIPTIN plasma
Homo sapiens
601.65 ng*h/mL
12.5 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
842.17 ng*h/mL
12.5 mg 1 times / day multiple, oral
ALOGLIPTIN plasma
Homo sapiens
1674.87999999999 ng*h/mL
25 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
3306.68 ng*h/mL
50 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
895.28 ng*h/mL
12.5 mg single, oral
ALOGLIPTIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
16.9 h
25 mg 1 times / day steady-state, oral
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
21 h
25 mg single, oral
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens
20.67 h
12.5 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
19.45 h
25 mg single, oral
ALOGLIPTIN plasma
Homo sapiens
17 h
50 mg single, oral
ALOGLIPTIN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
25 mg single, oral
[NO STEREO] ALOGLIPTIN plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily. Can be taken with or without food. Adjust dose if moderate or severe renal impairment or end-stage renal disease (ESRD).
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
JHC049LO86
Record Status Validated (UNII)
Record Version